Budesonide’s journey began as a response to the growing need for better anti-inflammatory drugs. Decades ago, researchers searched for steroid molecules that could target inflammation without wreaking havoc through harsh systemic side effects. The road led to budesonide, and in the process, a range of intermediates turned up—each a stepping stone in the creation of an important corticosteroid. Scientific documents from the late 1980s describe a slow grind, marked by experiments that fine-tuned both purity and activity. Chemists chiseled away at precursor structures, guided by methods rooted in trial, error, and increasingly detailed analytical techniques. Their persistence did more than fill pharmacy shelves. It paved a clearer path for making potent, well-tolerated treatments for asthma, IBD, and a handful of rare inflammatory syndromes. The historical record still holds lessons about flexibility and stubbornness, about choosing paths that balance breakthroughs with safety. That story isn’t just dusty archives; it lays the foundation for every lot produced today.
Budesonide intermediates stand out as core ingredients within modern pharmaceutical manufacturing. These chemical compounds, stepping stones to the finished drug, reflect a balance between cost, availability, and control of impurities. Companies leverage these molecules to build processes that stay robust against fluctuating raw material prices. Their properties directly influence how smoothly a batch of active drug comes together. Small changes in structure or residual solvents can ripple through manufacturing, affecting everything from crystal form to shelf-life. As the pharmaceutical industry comes under pressure to lower costs without losing sight of patient safety, intermediates like those for budesonide show up in boardroom discussions about competitiveness as much as they do in development labs.
Budesonide intermediates usually carry well-defined molecular weights with a crystalline or sometimes amorphous appearance. Many remain whitish solids, with melting points that sit near the boiling water mark or just above. Their solubility can vary sharply; some dissolve well in polar organic solvents, often acetonitrile or methanol, but stutter in water. Chemists watch for stability under normal light, moisture, and moderate heating. Small tweaks to their chemistry may stabilize or destabilize the intermediate, so handling often calls for gloves, eye shields, and tight container seals. The attention to every gram matters: traces of absorbed moisture or an unreacted side product can show up later as defects in the active drug. These intermediates rarely get discussed at the patient level, yet their reliability underpins the success of the entire formulation chain.
Technical data sheets for budesonide intermediates spell out purity in percentages, impurity thresholds, and allowed ranges for residual solvents. Each batch ties back by lot number. Labels hold more than an ID—there’s risk language and handling instructions. These pages give technicians a checklist, but they also offer a silent contract: if a batch lands out of spec, manufacturers risk batch rejection, regulatory heat, and damage to industry credibility. Barcode tracking, modern RFID chips, and electronic batch records make sure each kilogram moves through a transparent supply chain. The quality system loops back: what’s written on the label has to reflect what sits in the drum, no wishing it otherwise. No shortcuts stick in a system that answers to health authorities and, ultimately, the sickest patients.
Labs have sketched different routes over the years, but most industrial processes for budesonide intermediates follow a handful of core steps. Synthesis often begins with a steroidal backbone, modified through oxidation or esterification. Catalysis by carefully chosen acids or bases nudges the molecule toward an intermediate with the desired functional groups. The intermediate, still not active, then undergoes purification through crystallization, repeated washings, or modern chromatographic separation. Each step builds on decades of experience with unpredictability—temperature spikes, unexpected side reactions, or loss of product yield. Scale-up from bench to factory looks straightforward in textbooks, but in practice, technicians need to monitor pH, adjust temperatures within a half-degree, and test for contaminants with every batch. I’ve watched scale-ups stall on simple things: humidity in a storage tank, or a reactive impurity missed at five grams but not at five kilograms. No software replaces old-fashioned chemical instinct, so experience-rich teams remain critical here.
Transforming starting steroids to the final budesonide intermediate depends on selectivity and timing. Reactions like epoxidation, acylation, or dehydrogenation provide stepwise changes—add this group, remove that atom—without wrecking the molecule’s sensitive framework. Often, chemists chase yields in the 90% range, but trade-offs happen. Isolating intermediates sometimes means running reactions at low temperatures to suppress side-products. Scaling those same steps, plant engineers refine conditions, tweaking catalyst concentrations or stirring rates. Modern process safety protocols force re-examination of every step; toxic reagents used at small scale get swapped for greener alternatives at production levels. Solid-phase extraction and high-efficiency filtration clean up the output, shrinking impurity profiles and reducing load on downstream purification. Each reaction route carries its own quirks, and the best teams learn to diagnose trouble by smell, color, or the way crystals form in a flask. Chemical know-how forms the backbone, but the flexibility to adapt as regulations evolve means nobody’s job ever stands still.
Names shift from plant to plant, and sometimes even within the same company. Common synonyms include chemical shorthand, such as 16,17-acetal steroids or specific CAS numbers. Brand-level product names tend to carry in-house codes, a habit born from IP protection and competitive secrecy. These codes, meaningless outside the company, make sense only on the inside—but regulators demand alignment between production records and finished drug filings. Mislabeling or swap-outs cause headaches in manufacturing audit trails, reminding everyone of the central need for documentation discipline.
Worker safety around budesonide intermediates can’t get left to luck. Dusts raise inhalation risks, and liquid reagents may burn skin or eyes. MSDS sheets instruct on gloves, goggles, and fire control. Accidents spike in facilities treating these guidelines as optional, but the companies that thrive over the long haul build safety into culture. Fans keep air moving in process bays, while spill kits and high-grade PPE don’t linger on warehouse shelves but show up in daily use. Newer protocols adopt real-time environmental monitoring, picking up volatile emissions or pinhole leaks before they spiral into something bigger. Factory crews memorize emergency drills, signaling to outsiders that this isn’t just about compliance—it’s a way of working that protects livelihoods and upholds the trust placed by patients and regulators.
Budesonide intermediates feed into drug manufacturing lines that form the core treatments in pulmonology, gastroenterology, and rare disease fields. Their immediate users remain the pharmaceutical makers, but the finished drug’s impact ripples outward. For years, I’ve watched these intermediates make the leap from plant floors in Asia or Europe to clinics and pharmacies across the globe. Asthma, allergic rhinitis, and Crohn’s disease patients benefit from the reliability downstream. Doctors want predictability, and that starts upstream; if a batch of intermediate misses a quality cue, the entire chain can grind to a halt, delaying patient care. Consistent intermediate quality helps drugmakers avoid costly recalls and keeps new therapies moving from research to reality.
The R&D landscape for budesonide intermediates follows shifts in regulatory focus and patient demographics. Scientists dive into ways to cut down on leftover solvents, to sharpen the yield of new synthetic routes, or to minimize the formation of genotoxic byproducts. Advances like flow chemistry or biocatalysis open doors to cleaner, more efficient processes, though each has learning curves. I’ve seen research projects take small insights from academic chemistry and rework whole production lines in under a year. Partnerships with material scientists hint at coatings and delivery formats that once seemed science fiction. R&D doesn’t serve as a far-off division but feeds back lessons to current manufacturing—again, closing the loop that ties experiment with reality.
Regulators keep standards tight for intermediates, especially concerning impurities that might trail along with the finished product. Early-stage toxicology screens ejected certain intermediates from consideration altogether. Ongoing studies chase down trace components with sensitive analytical tools—mass spectrometry, NMR, or next-gen chromatographic techniques. Teams regularly report findings on in vitro and in vivo models, passing musters set by agencies like the FDA or EMA. No company wants a shortcut here; failures in toxicity oversight lead not just to public health risk but to reputational damage that’s hard to scrub. Manufacturers now design intermediates with “green chemistry” in mind, reducing reliance on suspect reagents and shrinking toxicity profiles wherever possible.
The outlook for budesonide intermediates ties to bigger trends in healthcare—rising demand for chronic disease management, pressure to cut drug costs, and increasing scrutiny on chemical sustainability. Improved synthetic routes hint at cheaper drugs and wider access, with greener processes that cut waste and lower the risk of occupational hazards. As therapies personalize based on patient genetics or biomarkers, intermediate purification and custom chemical tweaking may take center stage. The machines and people making these molecules could soon see more automation, faster feedback from AI analyzing production data, and tighter cybersecurity to protect trade secrets. Change never moves as fast as headlines predict, but with every new discovery, these intermediates keep evolving from a behind-the-scenes commodity into a critical ingredient powering tomorrow’s medicine cabinet.
Budesonide intermediate stands behind one of the main lines of defense for people with asthma and chronic obstructive pulmonary disease. The work that goes into making asthma inhalers or nasal sprays doesn’t get much attention, yet it holds real importance for those who depend on every breath. My own parent has been wrestling with adult-onset asthma, so tools like budesonide-based inhalers become essential for their daily comfort and ability to stay active.
Budesonide itself takes shape through several steps. This intermediate marks a crucial stage in the laboratory—where raw starting chemicals transform into a medicine that doctors trust to cut airway swelling and tamp down allergic reactions. Getting that right means fewer hospital visits and less worry for people with lung issues.
The World Health Organization lists budesonide as an essential medicine. The team effort to build its intermediates with tight quality control means medications stay safe and predictable. I’ve seen kids in grade school, at my local clinic, use these sprays to manage their wheezy lungs and keep up with their friends. It’s more than chemistry; it’s about helping folks lead steady lives with fewer interruptions.
Global demand for reliable inhalers keeps rising, especially after COVID-19 exposed the need for robust respiratory care. A sudden disruption in the supply chain of budesonide intermediate can send shockwaves through clinics and pharmacies. Not long ago, news of contamination or delays in pharmaceutical ingredients sent my local pharmacy into scramble mode, leading to anxious patients and overcrowded emergency rooms.
Safe practices in manufacturing go beyond technical checklists—they require workers with a strong sense of responsibility and companies that value transparency. The U.S. Food and Drug Administration keeps a careful eye on production sites, and countries such as India and China have stepped up their oversight as well. Mistakes or shortcuts lead to dire consequences, with the fallout always felt most by patients who have nowhere else to turn.
Inconsistent quality and price volatility hit the smaller companies and the people living paycheck to paycheck. Local clinics often cannot stock ahead, so a hiccup anywhere in this chemical supply chain lands squarely in the hands of those who are already vulnerable. Fact: Low-quality intermediates can make their way into the market if buying decisions prioritize cost over thorough vetting.
To cut risk, regulators and buyers need to know their sources and ask hard questions. I remember an outreach program at a community health center where staff pressed suppliers to provide proof of rigorous manufacturing. That kind of accountability keeps standards high and prevents trouble before it starts.
Smarter investments in training chemists and updating plants give everyone a better shot at safe medicines. Building strong ties between government, businesses, and researchers offers a path to sustainable supply lines. Quality doesn’t happen by accident or through last-minute fixes. It takes planning and people who care. Anyone who has watched a child breathe easier after a dose of their inhaler knows the value isn’t just in the chemistry, but in the peace of mind it brings.
Talking about storage conditions for Budesonide Intermediate might seem like splitting hairs, but it’s a real-world issue with real consequences. In the labs where researchers chase after the next big treatment for asthma or inflammatory diseases, a failure to store an intermediate right can knock months or even years off the shelf life of life-saving drugs.
Budesonide Intermediate won’t last long just sitting on any shelf. Storing it below 25°C keeps its chemical structure stable. Fluctuating temperatures can trigger breakdowns or impurities, which leads to batches that miss the mark. From personal experience, I remember a project delayed by weeks because humidity and temperature controls in a small facility got overlooked after a power cut. It felt maddening, watching paperwork pile up while we waited on new material. A reliable HVAC system isn’t a luxury in these labs—it's an insurance policy.
Leave any compound exposed to wet air, and the clock starts ticking on its purity. Budesonide Intermediate pulls in water molecules, sparking changes that show up in HPLC results and, down the line, in patient safety profiles. Keeping this intermediate in tightly sealed containers, far from humid spots, calls for real vigilance. Desiccants help, but tossing a silica pack into a jar is the bare minimum. I’ve seen researchers run emergency tests after realizing a container sat open for only a few minutes; the stakes are that high.
Direct sunlight and harsh fluorescent bulbs chip away at organic molecules over time. Shielding Budesonide Intermediate with opaque or amber containers isn’t about hiding it from curious eyes; it's about blocking photochemical reactions. Once, in a small-scale pilot facility, a single cracked container left under a bright lab lamp ruined a batch worth thousands. That’s a gut punch no project manager forgets.
Glass bottles often edge out plastic for sensitive intermediates. Glass doesn’t interact with chemicals the same way plastics sometimes do—avoiding leaching, warping, and static cling that can mess with powdery compounds. Screw-top lids with proper gaskets offer a solid seal. Every operator in charge of quality control learns fast: the right closure prevents more problems than it costs.
Tracking lot numbers and expiry dates isn’t a paperwork game. Accurate logs help trace contamination or loss of potency if something does go wrong. Good training means lab techs check twice before pulling the first bottle they see. I saw one team avoid a costly recall after quick-thinking staff flagged an off-smell in a batch, purely thanks to meticulous logs and constant training.
Tight space, spotty airflow, and crowded benches mess with even the best plans. Modern storage areas in pharma settings often feature climate control, humidity alarms, and backup generators. Installing automated systems can seem costly up front, but losing product and time in production makes the price worthwhile. Clear standard operating procedures, reinforced by ongoing staff education and routine audits, keep hard-won progress from slipping through the cracks.
The science keeps pushing forward, but the basics of storage still matter as much as drug design. Skimping on the essentials can kill a program before it leaves the lab. Every bottle, every batch deserves careful attention; for people depending on these treatments, that diligence can make all the difference.
Budesonide, a name I’ve seen over and over again in respiratory wards, stands as a lifeline for people dealing with asthma and inflammatory bowel disease. Those yellowish powders rolling off production lines hide a grittier story: any shortcut in the production process can end up on a patient’s pharmacy shelf. With budesonide intermediate, it’s not just about meeting a lab threshold; we’re really talking about the difference between medicine that heals and medicine that harms.
Pharma players and toxicologists generally set purity levels for budesonide intermediates at above 98%, with many top-tier manufacturers aiming for 99% or more. This scale isn’t an arbitrary number. That last little percent can mean the difference between a dose that’s predictably safe and one carrying impurities a patient’s body shouldn’t have to fight.
Physical appearance signals problems even before fancy machinery steps in. We’re looking for a white to off-white crystalline powder without odd coloring or clumping, both dead giveaways of contamination or improper handling. Solubility gets tested because a medicine that won’t dissolve right can’t work right—this hits patients hardest if overlooked.
The danger zone emerges not from what’s present, but from what isn’t supposed to be there. Even at microgram levels, possible irritants, residual solvents, or heavy metals matter. Good suppliers run tests like HPLC and GC to confirm impurities sit safely below 0.5%, and for some toxic residues, far lower—European and US pharmacopeial standards both back this up.
Water content lurks as an often-ignored spoiler. Once, I saw a batch of raw material wasted simply because moisture had crept over the 0.5% cutoff, making the whole run unstable. Loss on drying, along with sulfate ash content, rounds out the purity audit. An ash content higher than 0.1%, for instance, signals inorganic contamination.
Every number among these specs tells the story of safety. Budesonide breaks down inside the body to deliver relief where it’s needed. But any shortcut at the intermediate stage—be it sloppy filtration, incomplete crystallization, or skipping solvent checks—can produce side effects clinicians aren’t expecting. That scares anyone who walks hospital halls or talks with patients directly.
Sourcing teams and researchers should demand full certificates of analysis with impurity mapping down to the tenths of a percent. Third-party audits work best when factories open their testing logs, not just summary sheets. Regulatory harmonization, between European and US agencies, helps level the field and pushes makers away from “good enough” toward “best we can do.”
For folks on the patient side, trusting your inhaler or medication starts long before it hits a pharmacy bottle. Low impurities, clean water content, and detailed specs matter more than any branding pitch. From the quiet corners of chemistry labs to the pharmacies dispensing hope, purity levels in budesonide intermediate build the groundwork for real results and restored health.
Anyone keeping an eye on pharmaceutical supply chains probably knows the routine struggle—demand shoots up, production bottlenecks appear, and before anyone can blink, the market runs short of something crucial. Budesonide, commonly used in asthma inhalers and inflammatory bowel treatments, comes from key intermediates that anchor its manufacturing. Bulk availability isn’t just a matter of numbers or barrels stacked in a warehouse. It brings real consequences for companies, researchers, and ultimately, patients relying on these medicines.
The intermediates behind active pharmaceutical ingredients often fall into a gray area between commodity chemicals and specialized molecules. Decision-makers high up look for efficiency and cost, but they have to balance that with quality standards. I’ve seen companies lock themselves into long-term contracts that looked great on paper—until a pandemic changed everything. Sudden events make it painfully clear which suppliers built up a true inventory buffer versus those banking on just-in-time models. With Budesonide intermediates, some major chemical suppliers have built up decent capacity, but there’s a lot that can change once global health events or regulatory moves hit.
Bulk purchases offer a tempting price advantage. At the same time, the risk of cutting corners grows as order sizes scale up. In earlier days working with generic manufacturers, I saw plenty of deals fall apart when an intermediate didn’t match the specs promised on paper. Compliance with international standards like cGMP, traceability of raw material sources, and even basic batch testing often break down when the priority is moving volume above all else. Local manufacturing sometimes offers a safety net, but many countries lack the capacity or technical knowledge to produce these intermediates at scale.
Regulators set the standard, but enforcement looks wildly different across regions. For something like Budesonide intermediate, inconsistencies pop up in documentation, residue limits, and even transportation protocols. Bad actors find ways to push low-grade material, hoping buyers won’t notice slight quality drifts until it’s too late and clinical outcomes dip. Transparency from both suppliers and buyers—through independent audits and data sharing—keeps the worst risks in check. Real-world safety comes from companies willing to spend time tracking their supply chains, rather than just pulling quotes from email blasts.
Fixing the issue doesn’t require magic. It needs patient investment and genuine partnership between buyers and chemical suppliers. Multi-sourcing, buffer inventories, and direct engagement with manufacturers can shield against sudden shortages. Data sharing across the chain builds resilience, not just for the next quarter, but for years ahead. Governments and industry groups can push for better standards without stifling innovation. From past experience, firms who treat intermediates as basic commodities often find themselves scrambling later. Manufacturers committed to partnership—through joint ventures or capacity guarantees—gain an edge in both reliability and patient trust.
In the world of pharmaceuticals, Budesonide Intermediate stands out as a substance that calls for vigilance. Anyone who spends time in a lab or on a factory floor knows small oversights can bring big consequences. Budesonide Intermediate serves as a crucial step in creating medications that help millions breathe easier, but it's not something to take lightly. Safety around this chemical isn’t just red tape; it’s about preserving health, careers, and lives.
Years spent in labs have shown that inhaling, touching, or accidentally ingesting raw pharmaceutical ingredients can lead to skin rashes, respiratory irritation, or worse. Budesonide Intermediate often comes as a fine powder or a crystalline solid. Powders get airborne. It’s easy to lose track of how something invisible can still cause trouble. Simple mistakes—like not sealing containers or brushing powder off a glove—can lead to exposure.
Most incidents involve skin or eye contact. Gloves and goggles aren’t just for dramatic effect; they are basic shields. A face mask or respirator matters too, especially if even a trace of dust irritates the chest or throat. It’s not paranoia. There are stories out there about well-seasoned chemists dealing with years of asthma-like symptoms due to repeated low-level exposure. Lab coats, closed shoes, and chemical-resistant sleeves matter much more than people like to admit.
Any chemical that might get airborne needs to stay contained. Fume hoods aren’t just for show—they move the bad stuff away from your lungs. Even a minor spill can swiftly contaminate air or work surfaces. Having spent time in manufacturing settings, I know colleagues who brushed off a little dust, then spent weeks recovering from coughs and headaches. When weighing out Budesonide Intermediate, an enclosed system makes spills unlikely, but people make mistakes. Ventilation should work with you, not against you, drawing away loose powder before anyone notices.
Disposing of leftover material properly keeps colleagues and cleaning staff safe. Trying to cut corners and toss small amounts of waste in regular trash spreads risk far beyond the lab. Many companies install clear signage, specific bins, and frequent waste collection, because once a chemical reaches an untrained hand, problems snowball. Every time I saw waste bins near a lunch area or hand sinks, it made me rethink systems back in the lab.
Wiping down surfaces, double-checking containers, and logging every move takes time, but skipping these steps increases chances of accidental exposure, both for yourself and anyone else in the facility.
Every workplace storing Budesonide Intermediate ought to train their staff thoroughly. Videos and pamphlets rarely do enough. Real training means practice. Knowing where eye wash stations and showers are—and how fast you can reach them after a splash—makes a huge difference when seconds matter. Practice drills and walkthrough exercises stick in your memory far better than any checklist. Witnessing a real emergency, it struck me that panic disappears when people actually know the steps and can move without thinking.
Investing in better protective equipment, clear labeling, regular practice, and an environment where anyone can speak up about hazards makes all the difference. Sharing real stories about close calls pushes safety from theory to habit. Following guidelines isn't a box-ticking exercise—it's about keeping every pair of hands and eyes safe at the end of the shift.
| Names | |
| Preferred IUPAC name | (RS)-11β,21-dihydroxy-16α,17α-[butylidenebis(oxy)]pregn-4-ene-3,20-dione |
| Other names |
Budesonide EP Impurity B
16α,17-(Butylidenedioxy)pregn-4-ene-3,20-dione |
| Pronunciation | /ˌbjuːdɪˈsoʊnaɪd ˌɪntərˈmiːdiət/ |
| Preferred IUPAC name | (RS)-11β,21-Dihydroxy-16α,17α-[(1-methylethylidene)bis(oxy)]pregna-1,4-diene-3,20-dione |
| Other names |
Budesonide Impurity
Budesonide Related Compound Budesonide Intermediate I Budesonide Synthesis Intermediate |
| Pronunciation | /ˌbjuː.dəˈsəʊ.naɪd ˌɪn.təˈmiː.di.ət/ |
| Identifiers | |
| CAS Number | 51333-22-3 |
| Beilstein Reference | 4160286 |
| ChEBI | CHEBI:63639 |
| ChEMBL | CHEMBL1433 |
| ChemSpider | 21861196 |
| DrugBank | DB01222 |
| ECHA InfoCard | Budesonide Intermediate ECHA InfoCard: "03-2119980075-35-0000 |
| EC Number | 1317796-41-6 |
| Gmelin Reference | 731246 |
| KEGG | C06347 |
| MeSH | Budesonide |
| PubChem CID | 122089 |
| RTECS number | RGU8M80H39 |
| UNII | 08J41Q6T93 |
| UN number | UN3272 |
| CAS Number | 51333-22-3 |
| Beilstein Reference | 4170578 |
| ChEBI | CHEBI:76330 |
| ChEMBL | CHEMBL1433 |
| ChemSpider | 2156 |
| DrugBank | DB01222 |
| ECHA InfoCard | The ECHA InfoCard of product 'Budesonide Intermediate' is: **"03e4d957-0f3c-4193-8ebe-763b1542a938"** |
| Gmelin Reference | 1869098 |
| KEGG | C00019 |
| MeSH | D002164 |
| PubChem CID | 124337 |
| RTECS number | VD5244800 |
| UNII | 6S8NSW2M3I |
| UN number | UN2811 |
| Properties | |
| Chemical formula | C25H34O6 |
| Molar mass | 430.5 g/mol |
| Appearance | White or almost white powder |
| Odor | Odorless |
| Density | 1.2 g/cm3 |
| Solubility in water | Insoluble in water |
| log P | 2.3 |
| Vapor pressure | 0.00016 mmHg at 25°C |
| Acidity (pKa) | 12.71 |
| Basicity (pKb) | 8.2 |
| Refractive index (nD) | 1.528 |
| Viscosity | Viscous liquid |
| Dipole moment | 2.56 D |
| Chemical formula | C25H34O6 |
| Molar mass | 430.94 g/mol |
| Appearance | White or almost white crystalline powder |
| Odor | Odorless |
| Density | 1.2 g/cm³ |
| Solubility in water | Insoluble in water |
| log P | 1.61 |
| Vapor pressure | 4.6 x 10^-10 mmHg at 25°C |
| Acidity (pKa) | 12.35 |
| Basicity (pKb) | 12.96 |
| Refractive index (nD) | 1.528 |
| Viscosity | Viscous liquid |
| Dipole moment | 3.0042 D |
| Pharmacology | |
| ATC code | R03BA02 |
| ATC code | R03BA02 |
| Hazards | |
| Main hazards | May cause respiratory tract irritation, eye irritation, allergic reactions, and is harmful if swallowed. |
| GHS labelling | GHS02, GHS07 |
| Pictograms | GHS05,GHS07,GHS08 |
| Signal word | Warning |
| Hazard statements | H315: Causes skin irritation. H319: Causes serious eye irritation. H335: May cause respiratory irritation. |
| Precautionary statements | P264, P270, P280, P301+P312, P305+P351+P338, P337+P313 |
| Flash point | 140.7°C |
| Autoignition temperature | 210 °C |
| Lethal dose or concentration | LD50 (oral, rat): >2000 mg/kg |
| LD50 (median dose) | LD50 (median dose): 1312mg/kg (Rat, oral) |
| NIOSH | EM8988000 |
| REL (Recommended) | 30-40% |
| IDLH (Immediate danger) | Not established |
| Main hazards | Causes skin irritation. Causes serious eye irritation. May cause respiratory irritation. |
| GHS labelling | GHS02, GHS07 |
| Pictograms | GHS07, GHS08 |
| Signal word | Warning |
| Hazard statements | H315: Causes skin irritation. H319: Causes serious eye irritation. H335: May cause respiratory irritation. |
| Precautionary statements | P264, P261, P271, P272, P280, P302+P352, P304+P340, P305+P351+P338, P312, P332+P313, P337+P313, P362+P364 |
| NFPA 704 (fire diamond) | 2-1-0 |
| Flash point | Flash point: 137.6°C |
| Autoignition temperature | 400°C |
| LD50 (median dose) | LD50 (median dose): **1310 mg/kg (Rat, Oral)** |
| NIOSH | Not Listed |
| PEL (Permissible) | 15 mg/m3 |
| REL (Recommended) | 0.5 mg |
| IDLH (Immediate danger) | Not established |
| Related compounds | |
| Related compounds |
Budesonide
6β-Hydroxybudesonide Desisobutyryl budesonide Ciclesonide Beclomethasone dipropionate |
| Related compounds |
Budesonide
Dexamethasone Betamethasone Fluticasone Propionate Prednisolone |
Providing high-quality chemical products and logistics solutions for global trade partners.
